AGMB (AgomAb Therapeutics NV) Total Liabilities: $26.70 Mil (As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Total Liabilities?

AgomAb Therapeutics NV AGMB +0.85% 14 Total Liabilities is $26.70 Mil as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

AgomAb Therapeutics NV's Total Liabilities for the quarter that ended in Dec. 2025 was $26.70 Mil.

AgomAb Therapeutics NV's quarterly Total Liabilities increased from Dec. 2024 ($19.14 Mil) to Sep. 2025 ($21.95 Mil) and increased from Sep. 2025 ($21.95 Mil) to Dec. 2025 ($26.70 Mil).

AgomAb Therapeutics NV's annual Total Liabilities declined from Dec. 2023 ($21.62 Mil) to Dec. 2024 ($19.14 Mil) but then increased from Dec. 2024 ($19.14 Mil) to Dec. 2025 ($26.70 Mil).

AgomAb Therapeutics NV Total Liabilities Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Total Liabilities Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
47.05 36.81 21.62 19.14 26.70

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial 36.81 21.62 19.14 21.95 26.70
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AgomAb Therapeutics NV's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.767+(1.177+3.759
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=26.70

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=179.984-153.281
=26.70

AgomAb Therapeutics NV's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.767+(1.177+3.759
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=26.70

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=179.984-153.281
=26.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $26.70 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Total Liabilities of $26.70 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Total Liabilities too high?
AgomAb Therapeutics NV's current Total Liabilities is $26.70 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Total Liabilities compare to DNA and ACRS?
AgomAb Therapeutics NV's Total Liabilities of $26.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Total Liabilities is $26.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Total Liabilities of $26.70 Mil. The current Total Liabilities is $26.70 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Total Liabilities is $26.70 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price